Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis B virus

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87912 refers to the process of conducting an infectious agent genotype analysis specifically for the Hepatitis B virus (HBV) through nucleic acid testing, which can involve either DNA or RNA. This procedure is crucial for patients who have tested positive for HBV, a viral infection known for its potential to cause significant liver damage and increase the risk of liver cancer. The genotyping process involves amplifying and increasing the targeted DNA, which allows for the precise detection of the specific genotype of the virus. Understanding the genotype of HBV is essential as it can provide valuable prognostic information regarding the disease's progression and assist healthcare providers in determining the most appropriate antiviral treatment options for the patient. The analysis is performed on a blood sample, which is obtained through a separately reportable venipuncture. The serum or plasma from the blood sample is then subjected to testing methods such as polymerase chain reaction (PCR) or sequencing to accurately identify the HBV genotype.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The procedure indicated by CPT® Code 87912 is performed for the following conditions:

  • Positive Hepatitis B Virus Test Patients who have tested positive for Hepatitis B virus (HBV) require genotype analysis to determine the specific strain of the virus.
  • Assessment of Liver Damage Individuals with HBV may undergo this test to evaluate the potential for liver damage and the risk of developing liver cancer.
  • Guidance for Antiviral Treatment The genotype analysis provides critical information that can guide healthcare providers in selecting the most effective antiviral treatment options for managing HBV infection.

2. Procedure

The procedure for CPT® Code 87912 involves several key steps that ensure accurate genotype analysis of the Hepatitis B virus:

  • Step 1: Patient Preparation The patient is prepared for the blood draw, which may include explaining the procedure and obtaining informed consent. It is essential to ensure that the patient understands the purpose of the test and what to expect during the venipuncture.
  • Step 2: Venipuncture A qualified healthcare professional performs a venipuncture to obtain a blood sample. This step is critical as the quality of the sample can affect the accuracy of the test results. The blood is typically drawn from a vein in the arm using standard techniques to minimize discomfort and ensure safety.
  • Step 3: Sample Processing Once the blood sample is collected, it is processed to separate the serum or plasma. This step is necessary as the nucleic acid testing is performed on these components of the blood, which contain the genetic material of the virus.
  • Step 4: Nucleic Acid Testing The serum or plasma is subjected to nucleic acid testing methods, such as polymerase chain reaction (PCR) or sequencing. These techniques amplify the targeted DNA or RNA, allowing for the detection and identification of the specific HBV genotype present in the sample.
  • Step 5: Result Interpretation After the testing is complete, the results are analyzed and interpreted by a qualified healthcare professional. The identification of the HBV genotype provides essential information for prognosis and treatment planning.

3. Post-Procedure

After the procedure associated with CPT® Code 87912, patients may experience minimal discomfort at the venipuncture site, which typically resolves quickly. There are no specific post-procedure care requirements beyond standard care for a blood draw. Patients should be informed about the expected timeline for receiving test results and any follow-up appointments that may be necessary to discuss the findings and potential treatment options based on the genotype analysis. It is also important for healthcare providers to monitor the patient's liver function and overall health as part of ongoing management of HBV infection.

Short Descr NFCT AGT GNTYP ALYS HEP B
Medium Descr NFCT AGENT GENOTYPE ALYS NUCLEIC ACD HEP B VIRUS
Long Descr Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis B virus
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
Date
Action
Notes
2023-01-01 Note Short and medium descriptions changed.
2013-01-01 Added Added
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"